The role of milk protein and other dried milk products in the growth and development of stunted children

Conditions

Stunting Nutritional, Metabolic, Endocrine Stunting

Rolland Mutumba, Joseph Mbabazi, Hannah Pesu, Jack Windsor Lewis, Christian Mølgaard et al. (13 authors)

European Journal of Clinical Nutrition2025-03-31

Effects of lipid‐based nutrient supplements on gut markers in stunted children: Secondary analysis of a randomised trial

Hannah Pesu, Joseph Mbabazi, Rolland Mutumba, Otto Savolainen, Peter Riber Johnsen et al. (15 authors)

Journal of Pediatric Gastroenterology and Nutrition2025-03-03

10.1002/jpn3.70023

Correlates of Body Composition in Children with Stunting: A Cross-sectional Study in Uganda.

Lewis JI, Mbabazi J, Mutumba R, Ritz C, Filteau S, Briend A, Michaelsen KF, Mølgaard C, Wells JC, Mupere E, Friis H, Grenov B.

2024-08-051 citations

10.1016/j.tjnut.2024.08.001

Correlates of Plasma Citrulline, a Potential Marker of Enterocyte Mass, among Children with Stunting: A Cross-Sectional Study in Uganda.

Pesu H, Mbabazi J, Mutumba R, Savolainen O, Olsen MF, Mølgaard C, Michaelsen KF, Ritz C, Filteau S, Briend A, Mupere E, Friis H, Grenov B.

2023-12-214 citations

10.1016/j.tjnut.2023.12.027

Effect of Milk Protein and Whey Permeate in Large-Quantity Lipid-Based Nutrient Supplement on Early Child Development among Children with Stunting: A Randomized 2 × 2 Factorial Trial in Uganda

Joseph Mbabazi, Hannah Pesu, Rolland Mutumba, Gareth McCray, Kim F. Michaelsen et al. (12 authors)

Nutrients2023-06-072 citations

10.3390/nu15122659

Effect of milk protein and whey permeate in large quantity lipid-based nutrient supplement on linear growth and body composition among stunted children: A randomized 2 × 2 factorial trial in Uganda

Joseph Mbabazi, Hannah Pesu, Rolland Mutumba, Suzanne Filteau, Jack Windsor Lewis et al. (15 authors)

PLoS Medicine2023-05-2320 citations

10.1371/journal.pmed.1004227

The Role of Milk Protein and Whey Permeate in Lipid-based Nutrient Supplements on the Growth and Development of Stunted Children in Uganda: A Randomized Trial Protocol (MAGNUS).

Pesu H, Mutumba R, Mbabazi J, Olsen MF, Mølgaard C, Michaelsen KF, Ritz C, Filteau S, Briend A, Mupere E, Friis H, Grenov B.

2021-04-2410 citations

10.1093/cdn/nzab067

Interventions

Children in four study arms will receive a lipid-based nutrient supplement (LNS, 100 gram containing 530 kcal per day) with or without whey permeate and milk protein isolate using a 2-by-2 factorial d

Eligibility

Sex/Gender

All

Age

12 Months to 59 Months

Inclusion criteria

Inclusion criteria: 1. Age 12 - 59 months 2. Height-age-Z < -2 according to WHO growth standards (2006) 3. Care-taker able and willing to return for follow-up visits and agrees to phone follow-up 4. Living within the catchment area 5. Written informed consent given by parent/caregiver

Exclusion criteria

Exclusion criteria: 1. Severe acute malnutrition, defined as MUAC <115 mm OR WHZ<-3 OR bilateral pitting oedema 2. Medical complications requiring hospitalization 3. Obvious disability that impedes eating capacity 4. Disability that makes length/height assessment problematic 5. Participation in another study which impacts on this study or previous enrollment in this study 6. Family plans to move away from the catchment area in the next 6 months 7. History or known allergy to peanuts or milk

Design outcomes

Primary

Measure	Time frame
Measured at baseline and 12-weeks: 1. Knee-heel length (mm) 2. Height (cm)	—

Secondary

Measure	Time frame
Measured at baseline and 12-weeks: 1. Mid-upper arm circumference (mm) 2. Weight (g) 3. Height-for-age z-scores (HAZ) 4. Weight-for-height z-scores (WHZ) 5. Weight-for-age z-scores (WAZ) 6. Child development index (CDI) 7. Head circumference (cm) 8. Bioimpedance: Fat mass (FM, kg), fat-free mass (FFM, kg), fat mass index (FMI, kg/m2), fat-free mass index (FFMI, kg/m2) 9. Skin folds: triceps, subscapularis (mm) Blood tests: 10. Haemoglobin (g/L) 11. Serum/plasma insulin-like Growth Factor-1 (IGF-1) 12. Serum/plasma insulin 13. Serum C-reactive protein 14. Serum alpha-1-acid glycoprotein 15. Plasma citrulline 16. Serum ferritin and transferrin receptors (markers of iron status) 17. Plasma cobalamin and methylmalonic acid (markers of B12 status) 18. Plasma folate 19. Serum retinol Fecal tests: 20. Fecal myeloperoxidase 21. Fecal neopterin 22. Fecal alpha-1-antitrypsin 23. Gut microbiota 24. Morbidity (including diarrhea, pneumonia, fever, malaria), safety (deterioration to MAM or SAM and mortality) measured using patient records	—

Measure

Time frame

Measured at baseline and 12-weeks: 1. Mid-upper arm circumference (mm) 2. Weight (g) 3. Height-for-age z-scores (HAZ) 4. Weight-for-height z-scores (WHZ) 5. Weight-for-age z-scores (WAZ) 6. Child development index (CDI) 7. Head circumference (cm) 8. Bioimpedance: Fat mass (FM, kg), fat-free mass (FFM, kg), fat mass index (FMI, kg/m2), fat-free mass index (FFMI, kg/m2) 9. Skin folds: triceps, subscapularis (mm) Blood tests: 10. Haemoglobin (g/L) 11. Serum/plasma insulin-like Growth Factor-1 (IGF-1) 12. Serum/plasma insulin 13. Serum C-reactive protein 14. Serum alpha-1-acid glycoprotein 15. Plasma citrulline 16. Serum ferritin and transferrin receptors (markers of iron status) 17. Plasma cobalamin and methylmalonic acid (markers of B12 status) 18. Plasma folate 19. Serum retinol Fecal tests: 20. Fecal myeloperoxidase 21. Fecal neopterin 22. Fecal alpha-1-antitrypsin 23. Gut microbiota 24. Morbidity (including diarrhea, pneumonia, fever, malaria), safety (deterioration to MAM or SAM and mortality) measured using patient records

—

Countries

Uganda

Outcome results

None listed